1. 544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial. (26th November 2018) Authors: Kumar, Princy N; Weinheimer, Steven; Cohen, Zvi; Marsolais, Christian; Kuo, Kuei-Ling; Lewis, Stanley Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. (11th February 2021) Authors: Chemaly, Roy F; Marty, Francisco M; Wolfe, Cameron R; Lawrence, Steven J; Dadwal, Sanjeet; Soave, Rosemary; Farthing, Jason; Hawley, Stephen; Montanez, Paul; Hwang, Jimmy; Ho, Jennifer Hui-Chun; Lewis, Stanley; Wang, George; Boeckh, Michael Journal: Clinical infectious diseases Issue: Volume 73:Number 3(2021) Page Start: e773 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1. (4th October 2017) Authors: Emu, Brinda; Fessel, W Jeffery; Schrader, Shannon; Kumar, Princy N; Richmond, Gary; Win, Sandra; Weinheimer, Steven; Marsolais, Christian; Lewis, Stanley Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗